Objectif The NeoStrep project will develop a novel vaccine against Group B Streptococcal (GBS) infections, responsible for 50% of life-threatening infections in newborns. The aim is to provide a safe and effective alternative to current generally implemented antibiotic prophylaxis. Emergence of clinical isolates of GBS with reduced susceptibility to penicillin (the preferred prophylactic antibiotic) and pattern of genetic mutations in penicillin binding proteins of GBS is identical to that observed in Streptococcus pneumoniae prior to the breakthrough of true widespread penicillin resistance in that pathogen. Combined with already existing resistance to a wide range of other antibiotics, this indicates current GBS antibiotic prophylaxis is highly vulnerable to antibiotic resistance. Emergence of widespread antibiotic resistance threatens to return the incidence of GBS disease to pre-prophylaxis levels with the associated significant increases in health cost and morbidity/mortality caused by infections with resistant GBS.The NeoStrep project aims to eliminate the use of prophylactic antibiotics in GBS prevention and hence the problem of emerging antibiotic resistance in GBS through the development of a GBS vaccine.No approved vaccine currently exists, and one currently in development only covers a subset of clinical serotypes. The NeoStrep vaccine, which is based on a novel fusion protein approach, has a wider serotype coverage (95%) and is much cheaper to manufacture than the other GBS vaccine candidate in development. The vaccine is extensively validated in animal models, and a simple production method has been developed.The objective of the project is therefore to advance the vaccine through cGMP production, tox studies and into clinical trials, with the aim of generating proof of concept in humans by means of immunogenicity, response rate, durability and effect on spontaneous vaginal colonisation. Champ scientifique social sciencessociologydemographymortalitynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH.2013.2.3.1-1 - Drugs and vaccines for infections that have developed or are at the risk of developing significant anti-microbial resistance Appel à propositions FP7-HEALTH-2013-INNOVATION-2 Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur LUNDS UNIVERSITET Contribution de l’UE € 1 110 734,80 Adresse Paradisgatan 5c 22100 Lund Suède Voir sur la carte Région Södra Sverige Sydsverige Skåne län Type d’activité Higher or Secondary Education Establishments Contact administratif Bengt Johansson Lindbom (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (3) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire MINERVAX APS Danemark Contribution de l’UE € 3 141 498,35 Adresse VEDBENDVEJ 28 2900 HELLERUP Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Per Fischer (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée BIO-KINETIC EUROPE LIMITED Irlande Contribution de l’UE € 1 640 915,85 Adresse GREAT VICTORIA STREET 14 BT2 7BA BELFAST Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Crawford Maclean (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée CITOXLAB SCANTOX AS Danemark Contribution de l’UE € 106 023,00 Adresse Hestehavevej 36A 4623 Lille Skensved Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Andrew Makin (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée
